Studies of plasma prekallikrein in a family with prekallikrein deficiency were made. Three Children had no clotting activity but -35% antigen levels, and the mother and five children had twice as much prekallikrein antigen as clotting activity, suggesting the presence of a dysfunctional molecule. A nonfunctional variant form of prekallikrein was purified that contained no prekallikrein clotting activity. The variant and normal molecules were both 80,000 mol wt, immunologically indistinguishable and complexed similarly with high molecular weight kininogen. Isoelectric focusing studies suggested a difference of one charged amino acid residue. The variant was cleaved by #-Factor XIIa 200 times slower than the normal molecule, and no amidolytic activity was detected for the cleaved variant. These data and other observations suggest that an amino acid was substituted in the variant near the NH2-terminal end of the kallikrein light chain resulting in slower cleavage by #-Factor XIIa and the absence of enzymatic activity.
Introduction
Fletcher trait deficiency was first reported in 1965 by Hathaway et al. (1) . The asymptomatic clotting defect was characterized by a prolonged activated partial thromboplastin time that was thought to be due to the deficiency of a previously unrecognized clotting factor named Fletcher factor. Fletcher trait plasma was also shown to possess abnormalities in the generation of kinins, in kaolin-activated fibrinolytic activity (2, 3) and in the in vitro activation of plasma prorenin (4, 5) . In 1972, Wuepper (6) identified the Fletcher factor as plasma prekallikrein. Addition of purified plasma prekallikrein to Fletcher trait plasma corrected all abnormalities.
Since the original description ofthe Fletcher trait deficiency, several other families with a prekallikrein deficiency have been described (7) (8) (9) (10) . All samples from subjects with functional prekallikrein deficiency (1 1) . Samples from the other subjects were totally deficient in both functional and immunoreactive prekallikrein (CRM-). All CRM+ samples were from persons ofMediterranean extraction, whereas most CRM-samples were from Black Americans. The abnormal prekallikrein appeared indistinguishable from normal prekallikrein, as tested by immunologic techniques and gel filtration. Based on experiments using whole plasma, a defective activation of the abnormal prekallikrein was postulated.
In this study we report an additional family that includes three siblings whose plasma exhibits a total absence of prekallikrein functional activity. In plasma samples ofthese three family members, prekallikrein antigen was detected despite the absence of prekallikrein clotting activity. The abnormal prekallikrein molecule was isolated, characterized, and compared to normal prekallikrein. For this abnormal prekallikrein, we propose the name prekallikrein Long Beach (PKLB) after the city where this deficiency was detected.
Methods

Patient history
A 38-yr-old Caucasian woman entered the hospital for a hysterectomy for multiple leiomyomata. She indicated to the surgeon that one year earlier when she entered another hospital for a nasoplasty an abnormal preoperative coagulation screening test was detected but the surgery was performed without bleeding. Prior history including a tonsilectomy and teeth extractions also indicated no bleeding problem. At age 19 she had an episode of swollen legs and has had protein in her urine ever since. Family history indicated no bleeding problems in her parents, nine siblings, and one child. Her mother and one brother were on chronic hemodialysis for end stage renal disease not further characterized.
Prehysterectomy screening coagulation studies were performed. A prolonged activated partial thromboplastin time and normal prothrombin time were found. Mixing of her plasma with equal amounts of normal plasma, or plasma deficient in either Factor VIII, XI, or XII completely normalized the activated partial thromboplastin time. Mixing with prekallikrein-deficient plasma did not correct the clotting time. This suggested that the plasma of the patient was deficient in prekallikrein. In agreement with this, prolongation of the preincubation phase of the activated partial thromboplastin time resulted in a marked shortening of the clotting time. A specific prekallikrein clotting test using deficient plasma later confirmed the deficiency of prekallikrein. Based on this information, she had her hysterectomy without any problem.
Materials
All chemicals obtained from commercial sources were the best grade available. pH measurements were performed at room temperature. Protein concentration was determined by the method of Lowry et al. (12) using bovine serum albumin (Sigma Chemical Co., St. Louis, MO) as a reference.
Coagulation tests. The clotting activities of prekallikrein, Factor XI, Factor XII, and high molecular weight kininogen were determined using activated partial thromboplastin time assays as previously described (13, 14) . Prekallikrein, Factor XI and high molecular weight kininogen-deficient plasmas were obtained from George King Biomedical, Inc., Overland Park, KS. Factor XII-deficient plasma was obtained from a congenitally deficient patient. All plasmas were stored frozen at -70°C. One unit of prekallikrein, Factor XII, or high molecular weight kininogen clotting activity is defined as the amount of activity present in 1 ml of a normal plasma pool of 40 healthy donors.
Rocket immunoelectrophoresis of prekallikrein and high molecular weight kininogen were performed according to the method of Laurell (15) as described before (16) . The concentration of anti-prekallikrein and ofanti-high molecular weight kininogen antisera in the 0.9% agarose (SeaKem, FMC Co., Rockland, ME) solution in 25 mM sodium barbital buffer, pH 8.6, was 3 and 3.3%, respectively. Reference curves were made from the observed rockets for four twofold serial dilutions of a normal plasma pool of 40 healthy donors. One unit of prekallikrein or of high molecular weight kininogen antigen was defined as the amount present in I ml of the same normal plasma pool.
Antibodies directed against prekallikrein, Factor XII, and the light chain of high molecular weight kininogen were raised in goats with the use of Freund's adjuvant (Difco Laboratories, Detroit, MI). The antilight chain of high molecular weight kininogen ( 17) and the anti-Factor XII antiserum (18, 19) were monospecific without absorption. The antiprekallikrein antiserum was absorbed with a gamma globulin fraction in order to remove traces of contaminating antibodies (16) . The gamma globulin fractions of the antisera were prepared using DEAE-Sephadex A-50 (Pharmacia Fine Chemicals, Piscataway, NJ) followed by passage over concanavalin A-Sepharose (Pharmacia) as described previously (18) .
Purification of prekallikrein was performed according to a previously published method (20) using ion exchange chromatography on DEAESephadex and SP-Sephadex columns followed by affinity chromatography on a high molecular weight kininogen-Sepharose column. Traces ofcontaminating gamma globulin were removed by affinity chromatography on a column containing CNBR-Sepharose 4B (Pharmacia) to which immunopurified antibodies against the contaminating gamma globulin were convalently coupled as described elsewhere (1 1). The prekallikrein preparation was analyzed on 10% sodium dodecyl sulfate (SDS) polyacrylamide slab gels in the presence or absence of reducing agents and gave two protein bands with apparent molecular weights of 80,000 and 82,000. The purified prekallikrein contained 20 clotting units/mg protein.
PKLB was purified following the procedure used for the purification of normal prekallikrein. After the high molecular kininogen-Sepharose column, the fractions containing PKLB were pooled and dialyzed against a buffer containing 0.05 M MesNa, pH 5.1, 1 mM CaCl2, 1 mM MnCl2, 0.4 M NaCl, 1 mM benzamidine and 0.02% Na-azide. Affinity chromatography on concanavalin A-Sepharose (Pharmacia) at 4°C was then employed as described previously for Factor XI (14) . PKLB adhered to the concanavalin A-Sepharose and was subsequently eluted with 0.05 M Mes-Na, pH 5.1, containing 0.4 M NaCl, 1 mM benzamidine, 0.02% Na-azide, 5 mM Na4EDTA, and 0.5 M a-D-methyl glucoside (Sigma Chemical). The fractions containing PKLB were pooled and dialyzed against 4 mM sodium acetate, 2 mM acetic acid, 0.15 M NaCl, pH 5.3.
High molecular weight kininogen was purified from human plasma as a single polypeptide chain ofrelative molecular weight (Mr) = 1 10,000 as described before (14) . After incubation with plasma kallikrein, the light and heavy chains ofthe kinin-free high molecular weight kininogen were reduced, alkylated, and isolated as described previously (14) .
Human Factor XII was purified as described elsewhere (19) . /-Factor XIIa (Mr = 28,000) was prepared by incubation ofFactor XII with trypsin. ,8-Factor XIIa was then separated from trypsin and other Factor XII fragments using DEAE-Sephadex A-50 chromatography as described previously (18) .
All purified proteins were stored frozen at -70°C in storage buffer containing 4 mM sodium acetate, 2 mM acetic acid, 0.15 M NaCl, pH 5.3. Polyacrylamide gel electrophoresis in the presence of SDS was carried out on 10% slab gels (160 mm x 70 mm X I mm) according to Laemmli (21) . The gels were run at 6 mA for 18 h. The gels were stained for protein with Coomassie Blue R-250.
Isoelectric focusing of prekallikrein was performed on thin-layer polyacrylamide gels using LKB Ampholine PGA plates (LKB Instruments, Inc., Gaithersburg, MD) (pH range, 3.5-9.5). The procedure followed the manufacturer's instructions for the LKB 2117 Multiphor. The anode electrode solution was 1 M H3PO4 and the cathode electrode solution was I M NaOH. Samples (30-55 yd) were applied on 5 X 9 mm Whatman filter papers (Whatman, Inc., Clifton, NJ) that were deposited in the area equidistant from each electrode. A change in the constant power setting from 12 to 10 W was made after 45 min. During the 90-min experiment, the voltage increased from 340 to more than 1,000 V while the current dropped from 38 to 8 mA. As reference standards, ovalbumin, myoglobin, and chymotrypsinogen were used. The generation of amidolytic activity during the cleavage of PKLB by ,3-Factor XIIa was studied using the same reaction conditions as used for the cleavage experiment described above. During the incubation at 37°C, 10-Ml aliquots were withdrawn at several times and immediately mixed with 5 Ml ofanti-Factor XII gamma globulin fraction. After 5 min incubation at 37°C, a 7.5-Ml aliquot was then added to a plastic disposable cuvette (1 cm path length) containing 0. XIIa. Generation of amidolytic activity of PKLB was compared to the amidolytic activity generated during the cleavage of PKN by /3-Factor XIIa. The anti-Factor XII antibodies blocked 90% of the amidolytic activity of /3-Factor XIIa on S-2302. The amount of amidolytic activity generated by /3-Factor XIIa in the absence of anti-Factor XII antibodies was 1% of the amidolytic activity present after complete activation of PKN by /3-Factor XIIa.
Results
Family studies. The family tree of the propositus (II-2) is shown in Fig. 1 . Plasma samples of the parents of the propositus (II-2) and nine brothers and sisters were tested for the presence of prekallikrein, high molecular weight kininogen, Factor XI and Factor XII clotting activity and for prekallikrein (Fig. 2) and high molecular weight kininogen antigen level. The results are summarized in Table I . Three members of the family (II-2, II-6, and 11-8) had undetectable prekallikrein clotting activity levels (below 1% of normal), whereas prekallikrein antigen (Fig. 2) , was present in reduced amounts (35-43%). Several members, I- (Fig. 4) . PKLB gave a similar pattern but the bands focused at a pH that was 0.10 U lower than the pH of the PKN bands (Fig. 4) . Microheterogeneity of PKN based on isoelectric focusing studies has been previously reported (23, 24) .
Titration ofPKLB with high molecular weight kininogen or its isolated light chain. Since affinity chromatography on high molecular weight kininogen-Sepharose was used for the purification of PKLB, PKLB appears to bind to high molecular weight kininogen. A quantitative study was performed using previously described techniques (17) to study the binding of PKLB to high molecular weight kininogen or its light chain. This technique is based on the fact that normal prekallikrein does not migrate in agarose upon electrophoresis at pH 8.6. However, association of prekallikrein with high molecular weight kininogen or with its isolated light chain gives negatively charged complexes that are able to migrate at this pH. During Laurell rocket immunoelectrophoresis, maximum rocket heights are reached for prekallikrein when equimolar amounts of high molecular weight kininogen or of its alkylated light chain are present (17). Rocket immunoelectrophoresis experiments were carried out with PKLB. PKLB (1 ,g) was incubated for 20 min at 37°C in plastic tubes in the absence or presence of 0 to 4.4 Mg of high molecular weight kininogen or 0 to 1.7 Mg of alkylated light chain in 16 Ml of 25 mM sodium barbital buffer, pH 8.6. Aliquots (8 ,l) were analyzed by one dimensional rocket immunoelectrophoresis. PKLB alone migrated only slightly under these conditions, and it migrated much further after preincubation with either high molecular weight kininogen or its light chain (Fig. 5) . The heights ofthe rockets increased as a function ofincreasing high molecular weight kininogen or light chain concentration until a maximum height was reached. The observed rocket height as a function of the molar ratio of high molecular weight kininogen or ofits light chain to PKLB is seen in Fig. 5 . The titration data are fit using two straight lines as shown in Fig. 5 Figure 5 . Titration of PKLB with high molecular weight kininogen or its isolated light chain using Laurell rocket electrophoresis with antiprekallikrein antibodies. Aliquots (8 ,ug) containing 0.5 ,ug of prekallikrein were incubated with increasing amounts of high molecular weight kininogen or its light chain, as described in the text, and were then analyzed by rocket immunoelectrophoresis. The electrophoresis was performed as described in Methods in 0.9% agarose containing 3%
anti-prekallikrein -y-globulin. The rocket heights corresponding to the migration of PKLB were measured. The molar ratios were calculated by using the molecular weights of 85,000 for PKLB, 110,000 for high molecular weight kininogen and 40,000 for the isolated light chain.
proximately 50% was cleaved in 30-60 min. This indicates that the rate of cleavage of PKLB was -200 times slower than that ofPKN. Cleavage of PKLB resulted in fragments with very similar apparent molecular weights as formed during the cleavage of PKN. To compare the molecular weight of the fragments formed by cleavage of PKLB and PKN by (3-Factor XIIa, equal amounts of the fragments of PKLB and PKN present after 270 and 1 min, respectively, of incubation with (3-Factor XIIa were mixed and analyzed on a 10% SDS polyacrylamide slab gel alongside the same PKLB and PKN fragment samples. Fig. 7 shows the gel comparing these fragments. No difference in the size of the cleavage fragments of PKLB and PKN formed by (3-Factor XIIa was observed. This suggests that if there is a difference in molecular weight, it was less than -1,000. pearance of amidolytic activity. Since cleavage of PKLB by 1-Factor XIIa takes place, albeit at a much slower rate than that of PKN, the possibility was investigated if this cleavage was accompanied by the generation of kallikrein amidolytic activity toward the kallikrein chromogenic substrate, S2302. Using the same reaction conditions as described above for the cleavage experiment, aliquots were taken during the incubation period and mixed with anti-Factor XII antibodies. After 5 min incubation at 37°C the amidolytic activity was measured. No amidolytic activity was detected during the incubation of PKLB with ,B-Factor XIIa although full cleavage of the molecule had taken place as verified on reduced SDS polyacrylamide gels. PKN reached maximum activation after 1 min of incubation with ,BFactor XIIa. This indicates that, although complete cleavage of PKLB occurred, <1% of the amidolytic activity of PKN was generated during cleavage of PKLB by ,B-Factor XIIa.
Discussion
The family described in this paper with a CRM+ deficiency of prekallikrein was detected by a preoperative coagulation screening test of one of the members of the family. Additional investigations indicated a deficiency of prekallikrein clotting activity. The presence of a nonfunctional prekallikrein molecule was detected using rocket immunoelectrophoresis. Subsequent studies using plasma samples of other members of the family indicated that the father has -50% of normal levels of both prekallikrein antigen and activity, whereas the mother has one half of normal clotting activity but 93% The prekallikrein deficiency in this family appears to be clinically asymptomatic in agreement with other reports. Three members of the family have kidney disease, but only one of these three, the original patient in this study, has total absence of functional prekallikrein. Whether this has any relationship to the recently described activation of the renin-angiotensin system by plasma kallikrein (4, 5) remains to be established.
In order to characterize the defect of the abnormal prekallikrein molecule, PKLB was purified from a pool of plasma obtained from two members of the family. The purification procedure was similar to the procedure used for the purification of PKN. PKLB is indistinguishable from PKN when analyzed on SDS polyacrylamide gels. It appeared as a doublet with apparent molecular weight of 80,000 and 82,000 in the presence or absence of reducing agents.
The observations that PKLB is detected by rocket immunoelectrophoresis and that PKLB binds to high molecular weight kininogen-Sepharose as used in the purification procedure indicate that PKLB can bind to high molecular weight kininogen. Quantitative analysis of the complex formation of PKLB with high molecular weight kininogen or its light chain using the same rocket immunoelectrophoretic technique as used before for PKN (17) indicated that a one to one molar complex is formed and that the binding occurs via the light chain region of high molecular weight kininogen.
Saito et al. ( 11) were also unable to demonstrate a difference between normal prekallikrein and a nonfunctional prekallikrein using immunological techniques and gel filtration. Based on studies using plasma, they postulated a defective activation of the abnormal prekallikrein molecule. In our study the rate of cleavage of PKLB by (-Factor XIIa was -200 times slower than that of PKN, and the cleavage fragments of PKLB and PKN were indistinguishable when analyzed on reduced SDS polyacrylamide gels, suggesting that if the cleavage occurs at a different site the molecular weight difference between the normal and the PKLB fragments is < 1,000. The fact that complete cleavage of PKLB did not result in any detectable kallikrein amidolytic activity suggests that in the light chain region of the PKLB molecule a substitution of an amino acid has taken place that hinders the cleavage of the molecule by (-Factor XIIa and the expression of enzymatic activity by the active site. The result of the isoelectric focusing studies indicated that PKLB focused at a 0.1 pH unit different from PKN. This is consistent with the substitution of one positive amino acid for a neutral amino acid or of one neutral residue for a negative one. This amino acid replacement could alter PKLB such that both its proteolysis by j-Factor XIIa and its enzymatic activity are markedly altered. An alternative explanation for the different isoelectric focusing of PKLB could involve a difference in carbohydrate, e.g., sialic acid. Further chemical studies are necessary to identify the a'mino acid substitution or difference in glycosylation of PKLB. This may provide further insight in the structural requirements for a normal rate ofcleavage and a normal expression ofthe enzymatic active site of normal prekallikrein.
